Literature DB >> 15083270

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.

J Carlet.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15083270     DOI： 10.1007/s00134-004-2245-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  4 in total

1.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

2.  The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Steven P LaRosa; Howard Levy; Gary E Garber; Darell Heiselman; Gary T Kinasewitz; R Bruce Light; Peter Morris; Roland Schein; Jean-Pierre Sollet; Becky M Bates; Barbara G Utterback; Dennis Maki
Journal:  Crit Care Med       Date:  2003-09       Impact factor: 7.598

3.  International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee.

Authors:  C L Sprung; R G Finch; L G Thijs; M P Glauser
Journal:  Crit Care Med       Date:  1996-09       Impact factor: 7.598

4.  Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis.

Authors:  C Brun-Buisson; F Doyon; J Carlet; P Dellamonica; F Gouin; A Lepoutre; J C Mercier; G Offenstadt; B Régnier
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272
  4 in total
  2 in total

1.  The European Society of Intensive Care Medicine (ESICM) and the Surviving Sepsis Campaign (SSC).

Authors:  V Marco Ranieri; Rui P Moreno; Andy Rhodes
Journal:  Intensive Care Med       Date:  2007-02-16       Impact factor: 17.440

2.  Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

Authors:  Vania Costa; James M Brophy
Journal:  BMC Anesthesiol       Date:  2007-06-25       Impact factor: 2.217
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.